Open

Placebo controlled Phase 3 Trial of Descartes-08 in pateints with generalized Myasthenia Gravis

To understand the effectiveness and safety of Descartes-08 *study medication* in patients with generalized Myasthenia Gravis

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

Medical history, medication history, Myasthenia Gravis History- onset of disease, MG medications and change in doses, Quality of life questionnaires for patients. MG Assessments and any adverse effects. Blood draw at evey visit

Incentives

Reimbursement for mileage for travel to study site

In-person visits:
22

Total length of participation:
14 months

Looking for Specific Volunteers

Able to participate:

generalized Myasthenia Gravis

Not eligible if:

Pregnant or lactating
Severe disease or myasthenic crises

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Visit Study Website

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Secondary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

James Howard
Neurology

Study Type

Clinical or Medical
Interventional

Study Topics

Brain, Head, Nervous System

IRB Number

25-0551

ClinicalTrials.gov

NCT04146051

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.